Calendario›AMGN›Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
Ensayo de AMGEN INC en Immune Thrombocytopenic Purpura (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 41
- Centros
- 22
- Fin del objetivo primario
- nov 2015
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en jul 2014.
Qué mide
Successful self administration of romiplostim (First Standard of Care visit post Home Administration Training (range 2-8 weeks)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroCross-sectional study, observation made by healthcare professionals of subjects or caregivers, administering romiplostim at their first standard-of-care visit 4 weeks after training with the home administration training pack. Further observations can also be recorded in the study if made within 16 weeks of enrolment. Data will be collected from the subjects' dose diary at their first standard of care visit to ensure there were no problems with administration while not at the clinic.
Más ensayos de AMGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Inebilizumab | Fase 3 | En marcha, sin reclutar | abr 2024 (real) |
| inebilizumab · MINT | Fase 3 | En marcha, sin reclutar | may 2024 (real) |
| Tarlatamab · DeLLphi-304 | Fase 3 | En marcha, sin reclutar | ene 2025 (real) |
| Tarlatamab · DeLLphi-307 | Fase 2 | En marcha, sin reclutar | mar 2025 (real) |
| Maridebart Cafraglutide | Fase 2 | En marcha, sin reclutar | oct 2025 (real) |
| Erenumab Dose 1 · OASIS(EM) | Fase 3 | En marcha, sin reclutar | nov 2025 (real) |
Todos los de AMGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT02085993), actualizada en dic 2015.